Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
BiBBInstruments AB (publ) ("BIBB" or the "Company") today publishes an information document in connection with the rights issue of shares resolved by the Company's Board of Directors on 18 March 2026, based on the authorization from the extraordinary general meeting held on 13 March 2026 (the "Rights Issue"). If the Rights Issue is fully subscribed, the Company will receive approximately SEK 60 million before transaction costs. The Rights Issue is covered by subscription commitments and guarantee undertakings totaling approximately SEK 41.9 million, corresponding to approximately 69.5 per cent of the Rights Issue.
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION MEASURES.
The information document
In connection with the Rights Issue, the Company has prepared an information document in accordance with Article 1.4 (db) and Annex IX of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC.
The Company announces today that the information document has been registered with the Swedish Financial Supervisory Authority (Finansinspektionen) and is available on the Company's website, www.BibbInstruments.com, and on Vator Securities' website, www.vatorsecurities.se.
Summary of the Rights Issue
| Event | Date |
| Record date for participation in the Rights Issue | 26 March 2026 |
| Subscription period | 30 March - 13 April 2026 |
| Trading in subscription rights | 30 March - 8 April 2026 |
| Estimated date for announcement of outcome | 15 April 2026 |
| Estimated registration with the Swedish Companies Registration Office | Around 29 April 2026 |
| Estimated first day of trading with new shares on Spotlight Stock Market | Around 11 May 2026 |
Summary of terms
| Subscription price | SEK 0.37 per share |
| Issue volume | Approximately SEK 60 million if fully subscribed |
| Number of new shares if fully subscribed | 162,957,208 shares |
| Pre-emptive rights | Each existing share entitles the holder to four (4) subscription rights. One (1) subscription right entitles the holder to subscribe for one (1) new share. |
| Subscription commitments and guarantee undertakings | Approximately SEK 41.9 million, corresponding to approximately 69.5 per cent of the Rights Issue |
| Dilution if fully subscribed | Approximately 80 per cent |
| ISIN code subscription rights | SE0028329458 |
| ISIN code BTA (paid subscribed shares) | SE0028329466 |
| ISIN code share | SE0015987946 |
Advisors
Vator Securities AB is acting as financial advisor and Foyen Advokatfirma is acting as legal advisor to BiBBInstruments in connection with the Rights Issue. Nordic Issuing AB is acting as issuing agent.
This is a translation of the Swedish press release. If there should be any discrepancies, the Swedish language version prevails.
For further information, please contact:
Fredrik Lindblad, CEO
E-mail: [email protected]
Phone: +46 70 899 94 86
www.bibbinstruments.com
About BiBB
BiBBInstruments AB is a cancer diagnostics company that develops and commercializes EndoDrill®, the world's first series of powered endoscopic biopsy instruments with market clearance in the United States and CE marking in Europe. EndoDrill® is designed to collect core tissue samples (core needle biopsies, CNB) with high diagnostic accuracy and aims to improve the diagnosis of cancer in, among others, the stomach, pancreas, liver, lungs and urinary bladder. The product portfolio targets the global market for ultrasound-guided endoscopic biopsy instruments (EUS/EBUS), one of the most advanced and fastest-growing segments in modern endoscopy. BiBB received market clearance (510(k)) from the U.S. Food and Drug Administration (FDA) for its first instrument, EndoDrill® GI, in 2023 and obtained CE marking under the EU Medical Device Regulation (MDR) in 2024 for all three product variants: EndoDrill® GI, EndoDrill® EBUS and EndoDrill® URO. The U.S. launch of EndoDrill® GI was initiated in the autumn of 2025 in collaboration with TaeWoong Medical USA. The EndoDrill® system consists of sterile single-use instruments and a proprietary drive system. BiBB was founded in 2013 by Dr Charles Walther, a cancer researcher at Lund University and a senior consultant in clinical pathology at Skåne University Hospital. The company is headquartered at Medicon Village in Lund, Sweden, and its shares are traded on Spotlight Stock Market (ticker: BIBB).
Important information
Publication, release or distribution of this press release may in certain jurisdictions be subject to legal restrictions and people in the jurisdictions where this press release has been made public or distributed should be informed of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer or solicitation to buy or subscribe for any securities in BiBBInstruments in any jurisdiction, either from BiBBInstruments or from anyone else.
This press release is not a prospectus according to the definition in the Prospectus Regulation and has not been approved by any regulatory authority in any jurisdiction. No prospectus will be prepared in connection with the Rights Issue. The Company has instead prepared and published an information document in accordance with what is prescribed in Annex IX of the Prospectus Regulation.
This press release does not constitute an offer or solicitation to buy or subscribe for securities in the United States. The securities mentioned herein may not be sold in the United States without registration, or without an exemption from registration, under the U.S. Securities Act from 1933 ("Securities Act"), and may not be offered or sold within the United States without being registered, covered by an exemption from, or part of a transaction that is not subject to the registration requirements according to the Securities Act. There is no intention to register any securities mentioned herein in the United States or to issue a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, wholly or in part, in or to Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa, the United States or any other jurisdiction where the release, publication or distribution of this information would violate current rules or where such an action is subject to legal restrictions or would require additional registration or other measures beyond those that follow from Swedish law. Actions in contravention of this instruction may constitute a violation of applicable securities legislation.